WMSA
MLTX icon

Weiss Multi-Strategy Advisers’s MoonLake Immunotherapeutics MLTX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,336
Closed -$1.29M – 290
2023
Q4 		$1.29M Buy
+21,336
New +$1.1M 0.03% 409

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Weiss Multi-Strategy Advisers's MLTX Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2024, closing a stake of 21,336 shares — an estimated $1.29M sold.

Weiss Multi-Strategy Advisers first reported a position in MLTX in Q4 2023 and held it in 1 quarter. The position peaked at $1.29M in Q4 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining MoonLake Immunotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 21,336 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $1.29M.
  • Weiss Multi-Strategy Advisers first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's MoonLake Immunotherapeutics position peaked at $1.29M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.